Next Generation CAR-TCR SummitEngineering Smarter Adoptive Cell Therapies Share XNext Generation CAR-TCR Summithttps://pharmaphorum.com/events/next-generation-car-tcr-summit/
FDA halts Allogene CAR-T trial after safety scareA phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, Share XFDA halts Allogene CAR-T trial after safety scarehttps://pharmaphorum.com/news/fda-halts-allogene-car-t-trial-after-safety-scare/
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyIn 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the Share XAllogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyhttps://pharmaphorum.com/news/allogene-announces-pivotal-trial/
Collaboration is key to advancing cell therapy researchDr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company Share XCollaboration is key to advancing cell therapy researchhttps://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
NHS and Kite sign access deal for Kite’s cancer cell therapy TecartusNHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell Share XNHS and Kite sign access deal for Kite’s cancer cell therapy Tecartushttps://pharmaphorum.com/news/nhs-kite-cancer-therapy/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
Welcome to the CAR-TCR Summit Europe 2021Engineering s Cost-Effective Cure Share XWelcome to the CAR-TCR Summit Europe 2021https://pharmaphorum.com/events/welcome-to-the-car-tcr-summit-europe-2021/
